

April 2, 2026



Sigyn Therapeutics Launches Initiative to Evaluate Emerging Medical Technologies in Former NFL Players at Risk of CTE

SAN DIEGO, CA - April 2, 2026 ([NEWMEDIAWIRE](#)) - Sigyn Therapeutics, Inc. ("Sigyn" or the "Company") (OTCQB: SIGY), developer of CardioDialysis(TM), a medical device that enables continuous broad-spectrum clearance of inflammatory and pathogenic molecules from the bloodstream, today announced the launch of an initiative to evaluate emerging medical technologies in former NFL players at risk of chronic traumatic encephalopathy (CTE).

Former NFL players experience significantly higher rates of neurodegenerative diseases as compared to the general population. Among these are amyotrophic lateral sclerosis (ALS), Parkinson's disease, and CTE, which has been diagnosed post-mortem in a majority of former NFL players.

While repetitive head trauma is a known trigger for CTE initiation, chronic inflammation has been discovered to be the principal driver of disease progression.

Last month, researchers at Trinity College Dublin reported the protective blood-brain barrier (BBB) shield can be compromised by chronic inflammation and remain leaky for decades after an athlete retires from a sport involving repetitive head trauma. As a result, inflammatory and pathogenic molecules are able to leak into the brain, triggering neuroinflammation that can accelerate an abnormal accumulation of tau-protein, the hallmark indicator of CTE.

Based on this discovery, it is anticipated that many former NFL players could be living in a persistent state of hyper-inflammation that increases their risk for CTE.

In response, Sigyn Therapeutics is establishing a collaborative initiative to evaluate emerging medical technologies in former NFL players that have the potential to diagnose, monitor or treat CTE. The initiative plans to:

- Evaluate the feasibility of CardioDialysis, an extracorporeal blood purification technology to reduce the circulating presence of key inflammatory and pathogenic molecules that are known to fuel CTE progression.
- Complete an evaluation of blood-based neuron-derived exosome assays that offer to monitor CTE progression, response to therapies, and provide potential insight into changes in BBB permeability.
- Complete the evaluation of other candidate therapies including a tau vaccine and brain-delivered anti-inflammatory drug agent.

"Based on my previous participation in two landmark studies of CTE in former NFL players, the knowledge that the brains of collision sport athletes can remain permeable for decades opens the door to new strategies to diagnose CTE in the living and for treating the disease through a targeted control of inflammation," stated Jim Joyce, CEO of Sigyn Therapeutics.

The Potential Role of CardioDialysis in CTE

In the field of subtractive medicine, CardioDialysis is the first technology to integrate plasma separation and therapeutic adsorption into a single device that enables continuous broad-spectrum clearance of both inflammatory and pathogenic molecules from the bloodstream. This includes the clearance of inflammatory cytokines TNF-alpha, IL-1 beta, IL-6, as well as bacterial endotoxin. These are among the most relevant BBB-crossing contributors to CTE progression.

Related to CTE, excessive inflammatory cytokine production also increases gut permeability, allowing bacterial endotoxin to leak into the bloodstream, which further amplifies inflammation into the chronic self-perpetuating loop of neuroinflammation that was observed by the Trinity College researchers.

About Sigyn Therapeutics(TM)

Sigyn Therapeutics is the developer of CardioDialysis, a next-generation blood purification technology that enables continuous broad-spectrum clearance of inflammatory and pathogenic molecules from the bloodstream. Within the emerging field of subtractive medicine, CardioDialysis is the first therapy to integrate plasma separation and therapeutic adsorption within a single device. Based on mechanism, therapeutic opportunities include sepsis, life-threatening viral infections, neuroinflammatory disorders, and cardiovascular disease.

In the treatment of cardiovascular disease. CardioDialysis aims to reduce the circulating presence of inflammatory mediators that fuel cardiovascular disease progression while simultaneously lowering levels of cholesterol-transporting lipoproteins that contribute to heart attacks, strokes, and other Major Adverse Cardiovascular Events (MACE). Thus, overcoming the inherent limitations of single-target drugs. Based on its underlying mechanism, CardioDialysis is also being explored as a potential treatment for sepsis, life-threatening viral infections, and neurological disorders associated with systemic inflammation.

The Company's development pipeline is comprised of ImmunePrep(TM) to optimize the delivery of immunotherapeutic antibodies to treat cancer; ChemoPrep(TM) to enhance the targeted delivery of chemotherapy; and ChemoPure(TM) to reduce the toxicity of chemotherapy.

To learn more about Sigyn Therapeutics, visit: www.SigynTherapeutics.com

CONTACT:

Sigyn Therapeutics, Inc.

Jim Joyce
Inventor CEO

Email: jj@SigynTherapeutics.com

Cautionary Note Regarding Forward-Looking Statements

This information in this press release contains forward-looking statements of Sigyn Therapeutics, Inc. ("Sigyn") that involve substantial risks and uncertainties. All statements contained in this summary are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties. Statements containing words such as "may," "believe," "anticipate," "expect," "intend," "plan," "project," "will," "projections," "estimate," "potentially" or similar expressions constitute forward-looking statements. Such forward-looking statements are subject to significant risks and uncertainties, and actual results may differ materially from the results anticipated in the forward-looking statements. These forward-looking statements are based upon Sigyn's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Factors that may contribute to such differences may include, without limitation, the Company's ability to clinically advance Sigyn Therapy in human studies required for market clearance, the Company's ability to manufacture Sigyn Therapy, the Company's ability to raise capital resources, and other potential risks. The foregoing list of risks and uncertainties is illustrative but is not exhaustive. Additional factors that could cause results to differ materially from those anticipated in forward-looking statements can be found under the caption "Risk Factors" in the Company's Annual Report on Form 10-K, and in the Company's other filings with the Securities and Exchange Commission, including its quarterly Reports on Form 10-Q. All forward-looking statements contained in this report speak only as of the date on which they were made. Except as may be required by law, the Company does not intend, nor does it undertake any duty, to update this information to reflect future events or circumstances.

View the original release on www.newmediawire.com